AGIC-CAPITAL
30.11.2022 08:01:41 CET | Business Wire | Press release
AGIC Capital ("AGIC"), a growth-oriented private equity firm with $2.2 billion of assets under management, today announced that it had acquired a majority stake in ATEC Pharmatechnik GmbH ("ATEC" or "the Company"). The sellers, ATEC’s founder & CEO, Hans-Werner Mumm, and family-backed Mittelstand investor HANNOVER Finanz Group, will remain invested in the Company, and Hans-Werner Mumm will continue to act as its CEO.
ATEC is a leading manufacturer of aseptic processing solutions, primarily used in pharmaceutical manufacturing and bioprocessing applications, with a customer base that includes the top 10 global pharmaceutical companies. ATEC's products include stopper and cap processing systems used for aseptic filling, RTP transfer ports and ancillary single-use transfer bag solutions. These mission-critical technologies enable ATEC's customers to establish safe and reliable manufacturing process environments.
This is anticipated to be the first of several acquisitions as AGIC builds a specialty process technologies platform focused on pharmaceutical and biopharmaceutical end markets.
Hans-Werner Mumm, CEO of ATEC commented, "We are excited to partner with AGIC, a firm that shares our passion for providing our customers with safer aseptic transfer technologies, which are critical to the future of medicine. We look forward to expanding our critical role in pharmaceutical manufacturing and bioprocessing as we invest in our next phase of growth."
Erik Yankulin, Managing Director at AGIC, added, "ATEC supports the production of life-saving therapies by providing best-in-class aseptic transfer technologies to pharmaceutical and biopharmaceutical companies. Specifically, the Company's products provide industry-leading solutions for handling sterile drug products across the most demanding pharmaceutical manufacturing applications in the areas of diabetes, oncology and other therapies. We are excited to support ATEC through investments into new product development, go-to-market capabilities, and add-on acquisitions."
Frank Löffler, Partner at HANNOVER Finanz added, “We have worked closely with Hans-Werner and ATEC’s management team since 2018 to grow the business, its customer base and innovative product offering. We strongly believe in the company’s potential and wish AGIC as the future majority shareholder the best of success in driving the next chapter of ATEC’s growth.”
ATEC and HANNOVER Finanz were advised by Macquarie Capital with Latham & Watkins LLP advising the sellers, while AGIC was supported by White & Case LLP in connection with the acquisition.
About AGIC Capital
AGIC is a growth-oriented private equity firm that seeks to invest in thriving middle-market businesses focused on advanced industrial and healthcare technologies in Europe & beyond. AGIC’s differentiated investment strategy combines deep business model expertise, proactive thematic research, an unrelenting focus on the upside and a collaborative, management-first approach to value creation. Launched in 2015, AGIC currently has $2.2 billion in assets under management. The firm's more than 25 professionals are based in Europe and Asia. For more information about AGIC's investment philosophy, visit www.agic-group.com.
About ATEC Pharmatechnik GmbH
ATEC Pharmatechnik GmbH is a leader in stopper and cap processing solutions used for aseptic filling with patented process technology in pharmaceutical applications. ATEC’s products are used primarily in pharmaceutical manufacturing and bioprocessing applications and comprise stopper and cap processing systems used for aseptic filling, RTP transfer ports and ancillary single-use transfer bags and spare parts. The Company is headquartered in Sörup, Germany. www.atecgroup.de
About HANNOVER Finanz
HANNOVER Finanz Group has been a sought-after private equity partner for medium sized enterprises in all industries for more than 40 years now. The private equity firm is based in Hanover and Vienna and was founded in 1979 as one of the first providers of venture capital in Germany. Currently, the HANNOVER Finanz Group has over 700 million Euros of assets under management across around 40 companies in Germany and Austria. Since its foundation, the Group has invested an accumulated total of over one and a half billion Euros and has successfully completed more than 250 projects. For more information, please visit www.hannoverfinanz.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005602/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom